Northwest Permanente, Portland, Oregon.
JMI Laboratories, North Liberty, Iowa; United States Committee on Antimicrobial Susceptibility Testing (USCAST), Silverton, Oregon.
Diagn Microbiol Infect Dis. 2020 Jul;97(3):115053. doi: 10.1016/j.diagmicrobio.2020.115053. Epub 2020 Apr 1.
Based on antimicrobial susceptibility test interpretive breakpoint criteria from Clinical and Laboratory Standards Institute and United States Committee on Antimicrobial Susceptibility Testing, cefazolin uncomplicated urinary tract infection (uUTI) surrogate breakpoints do not accurately predict cefadroxil or cephradine susceptibility when testing indicated Enterobacteriaceae species isolates. Hence, these two orally-administered cephalosporins (OC) are not equivalent spectrum substitutes for cephalexin or six other related OC agents for contemporary uUTI therapy.
根据临床和实验室标准协会和美国抗菌药物敏感性试验委员会的抗菌药物敏感性测试解释性断点标准,头孢唑林治疗单纯性尿路感染(uUTI)的替代断点并不能准确预测头孢羟氨苄或头孢拉定对指示的肠杆菌科物种分离株的敏感性。因此,这两种口服头孢菌素(OC)与头孢氨苄或其他六种相关的 OC 药物在当代 uUTI 治疗中并非等效的广谱替代品。